{"entity":{"id":"paper-fight-202-pemigatinib-lancet-oncol-2020","kind":"paper","name":"FIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements","aka":[],"tldr":"The FGFR inhibitor pemigatinib shrank tumours in more than a third of patients with previously treated intrahepatic cholangiocarcinoma carrying FGFR2 fusions, the first targeted drug approved for the disease.","summary":"Phase 2 study of 146 patients with previously treated locally advanced or metastatic cholangiocarcinoma, including 107 with FGFR2 fusions or rearrangements, treated with pemigatinib 13.5 mg daily on a two-weeks-on, one-week-off schedule.\n\nIn FGFR2-rearranged patients objective response was 35.5 percent with median duration of response 7.5 months and median progression-free survival 6.9 months; no responses were seen in patients with other FGF/FGFR alterations. Hyperphosphataemia was almost universal.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2020","url":"https://doi.org/10.1016/S1470-2045(20)30109-1"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32203698/"}],"tags":[],"related":[],"cancers":["intrahepatic-cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pemigatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["fight-202"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30109-1","pmid":"32203698","authors":"Abou-Alfa GK, Sahai V, Hollebecque A, et al.","paperType":"observational","findings":["Objective response 35.5 percent in FGFR2-rearranged cholangiocarcinoma.","Median progression-free survival 6.9 months; median overall survival 21.1 months."],"whatItMeans":"FGFR2 fusion testing is standard in intrahepatic cholangiocarcinoma, and pemigatinib (with futibatinib) is the second-line targeted option for fusion-positive disease.","caveats":["Single-arm; the confirmatory first-line trial (FIGHT-302) is ongoing.","Hyperphosphataemia, eye toxicity and nail changes require monitoring."],"changedPractice":true,"participants":146},"route":"/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/","neighbours":{"cancer":[{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"drug":[{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/"}],"trial":[{"id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}